WallStSmart

HCA Healthcare, Inc. (HCA)vsMednax Inc (MD)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

HCA Healthcare, Inc. generates 3935% more annual revenue ($78.70B vs $1.95B). MD leads profitability with a 9.0% profit margin vs 8.6%. MD appears more attractively valued with a PEG of 0.24. MD earns a higher WallStSmart Score of 63/100 (C+).

HCA

Buy

57

out of 100

Grade: C

Growth: 4.7Profit: 7.5Value: 5.3Quality: 6.0
Piotroski: 5/9Altman Z: 1.71

MD

Buy

63

out of 100

Grade: C+

Growth: 4.0Profit: 6.5Value: 9.3Quality: 5.5
Piotroski: 5/9Altman Z: 1.71
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HCASignificantly Overvalued (-68.0%)

Margin of Safety

-68.0%

Fair Value

$316.29

Current Price

$494.99

$178.70 premium

UndervaluedFair: $316.29Overvalued
MDUndervalued (+64.6%)

Margin of Safety

+64.6%

Fair Value

$60.62

Current Price

$31.29

$29.33 discount

UndervaluedFair: $60.62Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HCA5 strengths · Avg: 9.0/10
Return on EquityProfitability
136.3%10/10

Every $100 of equity generates 136 in profit

Debt/EquityHealth
-7.4210/10

Conservative balance sheet, low leverage

Market CapQuality
$98.85B9/10

Large-cap with strong market position

P/E RatioValuation
15.7x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$1.10B8/10

Generating 1.1B in free cash flow

MD3 strengths · Avg: 8.7/10
PEG RatioValuation
0.2410/10

Growing faster than its price suggests

P/E RatioValuation
15.9x8/10

Attractively priced relative to earnings

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

Areas to Watch

HCA3 concerns · Avg: 4.0/10
Revenue GrowthGrowth
3.6%4/10

3.6% revenue growth

EPS GrowthGrowth
4.5%4/10

4.5% earnings growth

Altman Z-ScoreHealth
1.714/10

Distress zone — elevated risk

MD2 concerns · Avg: 4.0/10
Revenue GrowthGrowth
4.0%4/10

4.0% revenue growth

Altman Z-ScoreHealth
1.714/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : HCA

The strongest argument for HCA centers on Return on Equity, Debt/Equity, Market Cap. PEG of 1.43 suggests the stock is reasonably priced for its growth.

Bull Case : MD

The strongest argument for MD centers on PEG Ratio, P/E Ratio, Price/Book. PEG of 0.24 suggests the stock is reasonably priced for its growth.

Bear Case : HCA

The primary concerns for HCA are Revenue Growth, EPS Growth, Altman Z-Score.

Bear Case : MD

The primary concerns for MD are Revenue Growth, Altman Z-Score.

Key Dynamics to Monitor

HCA carries more volatility with a beta of 1.11 — expect wider price swings.

MD is growing revenue faster at 4.0% — sustainability is the question.

HCA generates stronger free cash flow (1.1B), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MD scores higher overall (63/100 vs 57/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

HCA Healthcare, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

HCA Healthcare is an American for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owns and operates 186 hospitals and approximately 2,000 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 21 states and the United Kingdom.

Visit Website →

Mednax Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

MEDNAX, Inc., provides neonatal, maternal-fetal, pediatric cardiology, and other pediatric subspecialties in the United States and Puerto Rico. The company is headquartered in Sunrise, Florida.

Visit Website →

Want to dig deeper into these stocks?